SBI Securities’s Protagonist Therapeutics PTGX Stock Holding History

SBI Securities’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.38K	Hold	70	–	–	﹤0.01%	1869
2025 Q4	$6.11K	Buy	+70	New	+$5.73K	﹤0.01%	1944

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

SBI Securities's PTGX Position: Q1 2026 in Review

SBI Securities held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 70 shares worth $7.38K. The position accounts for ﹤0.01% of the portfolio, ranked #1869.

SBI Securities first reported a position in PTGX in Q4 2025 and has held it in 2 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

SBI Securities held 70 shares of Protagonist Therapeutics worth $7.38K as of Q1 2026.
SBI Securities left its Protagonist Therapeutics share count unchanged in Q1 2026.
Protagonist Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #1869 holding.
SBI Securities first reported a position in Protagonist Therapeutics in Q4 2025 and has held it in 2 quarters since.
317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.